What innovations are being developed for AIDS and HIV?
With an estimated 39.0 million [33.1–45.7 million] people living with HIV at the end of 2022, and with 630 000 [480 000–880 000] people dying from HIV-related causes in 2022 alone[i] finding new ways of preventing, diagnosing, and treating the disease is crucial. To mark World AIDS Day 2023 we take a look at what innovations are being made in the diagnosis, management, and treatment of AIDS. To do this we initially ran a search for (Human-immunodeficiency-virus or HIV) or (Acquired-immunodeficiency-syndrome or AIDS) and limited it to the last 5 years. During this time, there have been over 11k patent publications relating to AIDS and HIV.
Figure 1 shows the patents are in a variety of classifications, and we can identify over a quarter of the publications related to classification codes A61P31/18 (for HIV), A61P35/00 (Antineoplastic agents), and A61P43/00 (Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00).
Who is Innovating for HIV and AIDS?
Figure 2Figure 2 shows Merke, the National Institute of Health Nih, and Viiv Healthcare dominate. We’ll highlight a few of their patents below.
Publication number US11648250B2
Title: TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS
Abstract: The present disclosure is directed to tetrahydroquinazoline derivatives of Formula Iand their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).
This patent discloses Tetrahydroquinazoline derivatives and their use as HIV-Targeted Activator of Cell Kill agents which accelerate the death of HIV GAG-POL expressing cells without concomitant cytotoxicity to HIV naïve cells.
National Institute of Health
Publication number US10815295B2
Title: BROADLY NEUTRALIZING HIV-1 ANTIBODIES THAT BIND TO THE CD4-BINDING SITE OF THE ENVELOPE PROTEIN
Abstract: Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed.
This patent discloses A method for inhibiting a human immunodeficiency virus (HIV)-1 infection in a subject by administering monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120.
Publication number US2023106880A1 – INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
Abstract: A compound of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection.
This application by Viiv Healthcare discloses novel compound that may be used in the treatment of human immunodeficiency virus (HIV) infection
At PatWorld, we understand the importance of protecting your #HealthTech inventions, and we can provide our clients with accurate, reliable, and cost-effective information and services tailored to meet individual needs.
For further information on our searches please visit our search options page Patent Search | Non-Patent Search | All Technologies (patworld.com).
If you enjoy our content here, you’ll love the stuff we share on LinkedIn, follow us now. Not on LinkedIn? Check out our other social media sites: